420 related articles for article (PubMed ID: 25723392)
1. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
[TBL] [Abstract][Full Text] [Related]
2. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
4. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
[TBL] [Abstract][Full Text] [Related]
5. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
6. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
8. Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas.
Secades P; Rodrigo JP; Hermsen M; Alvarez C; Suarez C; Chiara MD
Genes Chromosomes Cancer; 2009 May; 48(5):441-54. PubMed ID: 19235921
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
[TBL] [Abstract][Full Text] [Related]
10. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Pore N; Jiang Z; Gupta A; Cerniglia G; Kao GD; Maity A
Cancer Res; 2006 Mar; 66(6):3197-204. PubMed ID: 16540671
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-mediated downregulation of hypoxia-inducible factor-1α inhibits angiogenesis and survival of oral squamous cell carcinoma in vitro and in vivo.
Zhou H; Fei W; Bai Y; Zhu S; Luo E; Chen K; Hu J
Eur J Cancer Prev; 2012 May; 21(3):289-99. PubMed ID: 22113109
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma.
Wu K; Mao YY; Chen Q; Zhang B; Zhang S; Wu HJ; Li Y
Cell Oncol (Dordr); 2021 Oct; 44(5):1167-1181. PubMed ID: 34460078
[TBL] [Abstract][Full Text] [Related]
15. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
17. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
18. Ascochlorin inhibits growth factor-induced HIF-1α activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells.
Jeong JH; Jeong YJ; Cho HJ; Shin JM; Kang JH; Park KK; Park YY; Chung IK; Chang HW; Magae J
J Cell Biochem; 2012 Apr; 113(4):1302-13. PubMed ID: 22109717
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Lee JG; Wu R
Neoplasia; 2015 Feb; 17(2):190-200. PubMed ID: 25748238
[TBL] [Abstract][Full Text] [Related]
20. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]